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Role for the thromboxane 
A2 receptor β-isoform in the 
pathogenesis of intrauterine 
growth restriction
Katie L. Powell1,2,3,*, Veronica Stevens1,2,*, Dannielle H. Upton1,4, Sharon A. McCracken1,2, 
Ann M. Simpson4,5, Yan Cheng6, Vitomir Tasevski1,3,4, Jonathan M. Morris1,2 & 
Anthony W. Ashton1,2
Intrauterine growth restriction (IUGR) is a pathology of pregnancy that results in failure of the fetus 
to reach its genetically determined growth potential. In developed nations the most common cause 
of IUGR is impaired placentation resulting from poor trophoblast function, which reduces blood flow 
to the fetoplacental unit, promotes hypoxia and enhances production of bioactive lipids (TXA2 and 
isoprostanes) which act through the thromboxane receptor (TP). TP activation has been implicated 
as a pathogenic factor in pregnancy complications, including IUGR; however, the role of TP isoforms 
during pregnancy is poorly defined. We have determined that expression of the human-specific isoform 
of TP (TPβ) is increased in placentae from IUGR pregnancies, compared to healthy pregnancies. 
Overexpression of TPα enhanced trophoblast proliferation and syncytialisation. Conversely, TPβ 
attenuated these functions and inhibited migration. Expression of the TPβ transgene in mice resulted in 
growth restricted pups and placentae with poor syncytialisation and diminished growth characteristics. 
Together our data indicate that expression of TPα mediates normal placentation; however, TPβ impairs 
placentation, and promotes the development of IUGR, and represents an underappreciated pathogenic 
factor in humans.
Intrauterine growth restriction (IUGR) is defined as failure of the fetus to reach its genetically pre-determined 
growth potential1,2. IUGR can be diagnosed in utero by estimated fetal weight for gestational age less than the 
10th percentile, accompanied by Doppler ultrasound detecting decreased, absent or reversed end diastolic flow 
in the umbilical arteries1,3. IUGR is a leading cause of fetal mortality and morbidity, second only to pre-term 
delivery1,4–6; however, IUGR offspring that survive the perinatal period are at increased risk of cardiovascular 
disease and renal complications in adulthood7. Currently no biomarkers exist that predict pregnancies at risk of 
developing IUGR nor are there effective preventative treatments. In the absence of effective prophylaxis or treat-
ment the growth restricted fetus is delivered early, often pre-term, which contributes further to the risk of adverse 
neonatal outcomes8.
IUGR can be classified as either symmetrical or asymmetrical. Symmetrical IUGR results from maternal fac-
tors (such as malnutrition and alcohol consumption) and congenital infections. Conversely, asymmetrical growth 
primarily arises from the presence of a placental pathology2,9. Placentae of growth restricted pregnancies are 
smaller in weight, have reduced number and diameter of villi and a reduction in the number and area of capillar-
ies within the villi indicating impaired vascularisation and branching angiogenesis10–12. They also exhibit greater 
rates of infarction, fetal vessel thrombosis and chronic villitis than the placentae of normal pregnancies13. These 
placental pathologies are precipitated by morphological and biochemical abnormalities at the cellular level. IUGR 
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placentae display increased apoptosis, reduced cytotrophoblast proliferation, diminished syncytiotrophoblast 
area with an increased number of nuclei present indicative of compromised syncytialisation10,12,14. Insufficient 
trophoblast invasion, with failure to remodel spiral arteries, is also present15,16. The abnormal trophoblast func-
tion and reduced placental vascularisation shift the physiologic equilibrium in the placenta promoting placental 
hypoxia and ultimately oxidative stress10.
Reactive oxygen species (ROS), produced in response to oxidative stress, initiate damage to a variety of intra-
cellular molecules including DNA, protein and membrane lipids. Peroxidation of the membrane lipid arachidonic 
acid results in the formation of F-series isoprostanes, which are markers of oxidative stress17,18. However, isopros-
tanes are also biologically active and exert their effects through activation of the thromboxane (TX)A2 recep-
tor (TP)17,19. Bone fide TXA2 generation is also perturbed in IUGR with the TXA2:prostacyclin ratio increased 
in maternal serum and perfusates of the placental circulation from IUGR pregnancies compared to those with 
“normal” outcomes20,21. TXA2 overproduction by placentae and platelets is prevalent in human pregnancies com-
plicated by cigarette smoking22, diabetes mellitus23 and alcohol consumption24 which are associated with IUGR. 
Furthermore, infusion of TXA2 analogues (such as U46619 and STA2) into rodents produces a IUGR-like syn-
drome characterised by a 10–15% reduction in pup weight, which persisted until 28 and 77 days post-partum 
for male and female offspring, respectively25–27. The pups from these pregnancies exhibit a pattern of growth 
restriction characteristic of asymmetrical IUGR with reduced body/liver weight with sparing of brain changes in 
weight or energy metabolites25,28,29. Moreover, TP antagonists block the vasoconstriction and normalised pup and 
placental weight in rodent models associated with IUGR30,31, suggesting a strong causal role for TXA2 in disease.
The role of the TP is well established in a number of diseases; however, very little information exists on the 
role of the specific isoforms during pregnancy. The G-protein coupled TP has two isoforms in humans, TPα and 
TPβ , derived from alternate splicing of a single gene32,33. Both isoforms are identical through the first 328 amino 
acids but differ in the length of the cytoplasmic C-terminus (with the tails 15 and 79 amino acids for TPα and 
TPβ , respectively). The cytoplasmic tail is a poor discriminator of G-protein coupling34,35 promoting complacency 
over the differential role of these two isoforms in human disease. Our study sought to identify the complement 
of TP isoforms expressed in placentae from normal, healthy and IUGR affected pregnancies and to understand 
the differential regulation of trophoblast function by TPα and TPβ . We have identified enhanced TPβ protein 
expression in placentae from IUGR pregnancies compared to those from normal pregnancies. Moreover, we 
demonstrate that enhanced TPβ expression impairs trophoblast function promoting placental insufficiency that 
is characteristic of IUGR. Pup weight and placental density in the TPβ -transgenic mice are significantly reduced 
and trophoblasts in these placentae exhibit impaired proliferation and syncytialisation consistent with IUGR in 
humans. In conclusion, we propose that dysregulation of TP isoform expression in the placenta is a significant 
cause of spontaneous IUGR in human pregnancy, which is amenable to targeted therapy to prevent both the short 
and long term mortality and morbidity associated with this condition.
Results
TPβ expression is increased in the syncytial layer of placentae from growth restricted preg-
nancies. The distribution and expression of TP isoforms in placental tissue, and whether this changes during 
IUGR, has not been documented. We assessed TP isoform expression in third trimester placental tissue from 
“normal” uncomplicated pregnancies and those affected by IUGR (Table 1). As expected, the birth weight of 
babies from IUGR pregnancies was significantly lighter (P = 0.004) compared with those from control gestation-
ally matched pregnancies (Table 1). Immunoblotting of placental protein extracts revealed a 2.8 fold increase in 
overall TP expression in IUGR placentae (P < 0.005) (Fig. 1a). This was associated with increased expression of 
both TPα (1.6 fold; P = 0.017) and TPβ (2.6 fold; P < 0.005) (Fig. 1a) after normalisation to the loading control. 
When examined by IHC, TPα expression was ubiquitous in control placentae (including the syncytiotrophoblast 
layer, endothelial cells and villous stroma); however, TPβ expression was essentially absent, with any staining 
primarily restricted to the endothelium of villous blood vessels (Fig. 1b, arrows). Conversely, TPβ expression 
was markedly increased in the syncytiotrophoblast layer in IUGR tissues while TPα expression was not different 
(Fig. 1b). TP isoforms are regulated by alternative splicing. Transcript levels for Total TP and TPα did not change 
in IUGR; however significantly lower expression of TPβ was evident in IUGR compared to control placental tis-
sues (Fig. 1c). This change in TPβ gene expression also contributed to a change in the ratio of TPα :TPβ (Fig. 1c). 
These data suggest that neither transcription nor alternate splicing were responsible for the enhanced TPβ protein 
expression and that protein stabilisation is the most likely explanation.
Subgroup Maternal Age BMI SBP (mm/Hg) DBP (mm/Hg)
Gestational Age at 




(n = 53) 31.5 (5.0)* 24.9 (6.1) 113.5 (12.4) 67.6 (10.7)* 34.0 (4.4) 2443.0 (989.2)* * * 67.9%/32.1%
IUGR 
(n = 22) 34.1 (3.9) 22.6 (3.2) 119.6 (14.7) 75.2 (10.1) 35.6 (2.9) 1745.0 (632.3) 45.4%/54.5%
Table 1.  Clinical data on placental samples from “normal” and IUGR affected pregnancies. Clinical 
characteristics are shown for the control (gestationally matched) and IUGR patients recruited for placental 
sample collection. Data include maternal age, body mass index (BMI), systolic (SBP) and diastolic (DBP) blood 
pressure, gestational age at delivery, birth weight and fetal gender. Data are represented as mean (SD) (n = 53 
and 22). Independent samples T-test, * P < 0.05, * * * P < 0.005.
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TP isoforms differentially regulate trophoblast proliferation. To explore the individual role of TP 
in placentation we characterised the effects of TPα and TPβ in the choriocarcinoma cell lines, BeWo and JEG-3, 
commonly used as in vitro models of placental development. Both BeWo and JEG-3 cells constitutively expressed 
low levels of TPα but no TPβ (Supplementary Fig. S1). Transfection and stable selection of TPα , TPβ and the “tail-
less” deletion mutant (TPΔ 328) led to a 5–10 fold increase in receptor expression at the protein level compared to 
empty vector (∅ ) transfected cells (Supplementary Fig. S1). Overexpression of TPΔ 328 or TPα conferred no growth 
advantage compared to ∅ transfected cells or untransfected BeWo (Fig. 2a) or JEG-3 (Fig. 2b) cells. However, acti-
vation of TPβ ablated proliferation in BeWo cells (P = 0.014) and reduced growth of JEG-3 cells by 30% (P = 0.001), 
(Fig. 2a,b, respectively). Thus, TP isoforms show specific and opposite regulation of trophoblast function.
Figure 1. TPβ is highly expressed in IUGR placentae but is absent from healthy placentae. (a) Slot blots on 
lysates from normal, healthy placentae and placentae from pregnancies complicated by IUGR were probed with 
antibodies to identify total TP expression and that of the two isoforms (TPα and TPβ ) in addition to a loading 
control (Histone H1) (n = 17 control and 15 IUGR placentae). (b) IHC on paraffin-embedded sections from 
normal, healthy placentae and placentae from pregnancies complicated by IUGR were probed with antibodies 
to TPα and TPβ . Sections were imaged at 200x magnification, scale bar: 100 μ m; arrows indicate staining in 
vascular endothelium (n = 53 control and 22 IUGR placentae). (c) Quantitative gene expression of total TP, 
TPα and TPβ (and change in the ratio of TPα :TPβ ) relative to HPRT1 expression was assessed in the same 
placental samples analysed in (a) (n = 13 control and 12 IUGR placentae). Data represent individual samples 
(mean ± SEM); Independent samples T-test, NS: not significant, *P < 0.05, **P < 0.01.
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Proliferation is a balance between cell division and cell death. Examination of apoptosis by flow cytometry, 
either at baseline or under serum-starvation conditions, did not show differences between any of the TP trans-
fected cell lines and the ∅ control (Fig. 2c). Therefore the effects of TPβ on trophoblast growth must be related 
to cell cycle progression. Examination of randomly cycling cells indicated expression of TPΔ 328 had no effect on 
BeWo cell cycle progression compared to ∅ transfected or untransfected BeWo cells (Fig. 2d). TPα over expres-
sion elevated the number of cells in S-phase (Fig. 2d) suggesting enhanced G0/G1 exit which was confirmed by 
reduced ability to arrest cells with L-Mimosine (Supplementary Fig. S2) and enhanced S-phase entry within 
24 hours of withdrawal of L-Mimosine (Supplementary Fig. S2). This was accompanied by enhanced phospho-
rylation of Ser780 and Ser795 in Rb in TPα expressing cells (Fig. 3a), the product of enhanced expression of Cyclin 
A (3.2 fold), D1 (2.6 fold) and CDK6 (4.1 fold) (Fig. 3b,c). Conversely, TPβ activation promoted accumulation of 
cells in the G2/M phase (Fig. 2d) suggesting the reduced proliferation was due to an inability to complete cell divi-
sion. This phase of the cell cycle is driven by Cyclin B-CKD1 complexes, which appear to be normally expressed in 
TPβ -BeWo cells (Fig. 3b). However, expression of the cell cycle inhibitor proteins p21 (5.2 fold), p27 (3.9 fold) and 
p53 (2.6 fold) were all increased with TPβ overexpression compared to TPα , TPΔ 328, ∅ and untransfected BeWo 
cells (Fig. 3d; P < 0.05). Therefore the cells were unable to progress through the G2/M phase causing inhibition 
of TPβ cell proliferation (Fig. 2a).
TPβ expression reduces BeWo syncytialisation. Another essential function for placentation is forma-
tion of the fetal-maternal interface, which is lined by multinucleate syncytiotrophoblasts resulting from mem-
brane fusion (syncytialisation). The high expression of TPβ in the syncytium of the growth restricted placentae 
(Fig. 1b) strongly suggested this function would be regulated by TPβ . Treatment of BeWo cells with the TP agonist 
I-BOP (200 nM) did not affect basal expression of E-cadherin or syncytin by BeWo cells (Supplementary Fig. S3). 
Conversely, forskolin treatment (100 μ M) reduced E-cadherin and augmented syncytin expression by immuno-
fluorescence (Fig. 4a) and immunoblotting (Fig. 4b) which are both markers of syncytialisation. TPα activation 
Figure 2. Differential effects of TP isoforms on trophoblast cell cycle. (a) Proliferation of BeWo cells (□ ) 
transfected with empty vector-∅ ( ), TPΔ 328 (O), TPα (■ ) and TPβ (∙) was monitored over 168 hours. 
(b) Proliferation of JEG-3 cells expressing similar constructs, stimulated with vehicle (□ ) or 100 nM I-BOP (■ ) 
was documented over the same period. (c) Apoptosis of BeWo cells under basal (□ ) and serum-deprivation (■ ) 
was assessed after 24 hours using flow cytometry. (d) Distribution of transfected BeWo lines in phases of the cell 
cycle (G0/G1 □ , S , G2/M ■ ) was assessed also using flow cytometry. The data are represented as mean ± SEM 
and are representative of 3 independent experiments. One-way ANOVA and Independent samples T-test,  
* P < 0.05, * * P < 0.01, * * * P < 0.005.
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on BeWo cells accelerated loss of E-cadherin (40% compared to 16% in ∅ cells; Fig. 4a,b) and enhanced syncytin 
expression (2.5 fold; Fig. 4b) compared to untransfected and ∅ expressing cells (Fig. 4a). TP∆ 328 did not augment 
E-cadherin loss but significantly increased syncytin expression (1.15 fold gain) indicating the effects of TPα on 
differentiation were mediated by both isoform specific (E-cadherin loss) and common (elevated syncytin expres-
sion) pathways (Fig. 4a,b). Conversely, TPβ -BeWo cells retained more E-cadherin membrane staining and higher 
expression by immunoblotting, with no induction of syncytin expression after forskolin treatment (Fig. 4a,b). 
Collectively these data suggest that TPα promotes syncytialisation during placentation while TPβ expression 
abrogates the process. These findings are consistent with the expression pattern of TP isoforms with high TPα 
expression in “normal” pregnancies promoting robust placentation while TPβ promotes insufficient placentation 
associated with pathological pregnancies.
TPβ expression slows trophoblast cell migration. A key step in the pathogenesis of asymmetric 
growth restriction is the invasion of the uterine wall and remodelling of spiral arteries by cytotrophoblasts. The 
role of TP isoforms in regulating this process is undocumented. Motility of ∅ and TPΔ 328 transfected JEG-3 
cells was unchanged, compared to untransfected cells, in the presence of I-BOP (Fig. 5a). TPα -JEG-3 cells had 
a mild reduction (14%) in migration compared to ∅ controls (P < 0.001), but not compared to TPΔ 328-JEG-3 
cells (P = 0.160) (Fig. 5a). TPβ overexpression reduced migration (36%) which was significant compared to ∅ 
(P < 0.001), TPΔ 328 (P < 0.001) and TPα (P < 0.001) expressing cells (Fig. 5a).
Migration of cells is a complex process regulated by cytoskeletal dynamics, extracellular matrix (ECM) 
interactions and planar cell polarity. To determine the mechanism by which TPβ activation inhibited troph-
oblast migration we examined adhesion of cells to several matrix components. Consistent with the migration 
data, transfection of JEG-3 cells with ∅ , TPΔ 328 and TPα did not influence binding of trophoblasts to matrix 
components (Fig. 5b). Conversely, activation of TPβ enhanced JEG-3 attachment to collagen I and collagen IV 
based matrices (3 fold and 2.5 fold, respectively) while attachment to fibronectin and vitronectin was unchanged 
(Fig. 5b). This was significantly different to ∅ -JEG-3 (P = 0.025) and TPΔ 328-JEG-3 (P = 0.01) cells when binding 
to collagen I. Thus, the blunted migration in TPβ -JEG-3 cells might be explained by enhanced adhesion to ECM.
To further determine the role of adhesion in the inhibition of trophoblast migration by TPβ we examined 
focal adhesion formation in these cells. Association of vinculin with integrins denotes focal adhesion com-
plexes actively engaged with matrix binding and is therefore implicated in the control of cell motility36,37. I-BOP 
Figure 3. TP isoforms differentially regulate the molecular machinery controlling cell cycle progression. 
Immunoblotting of BeWo cells transfected with empty vector (∅ ), TPΔ 328, TPα and TPβ was used to examine 
pRb phosphorylation (a), Cyclins (b), Cyclin-dependent kinases (CDK) (c) and tumour suppressor proteins 
(d). Non-phosphorylated Rb was used as the loading control in panel (a) and GAPDH was used as the loading 
control in panels (b-d). Blots are representative of 4 individual experiments. Densitometry was used to quantify 
changes in protein expression and activation status.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:28811 | DOI: 10.1038/srep28811
treatment of TPα -JEG-3 cells (Fig. 5c) reduced the levels of vinculin staining (both size and number of focal 
adhesions) compared to ∅ and TPΔ 328 transfected cells (which were no different to untransfected cells) which is 
indicative of fewer focal adhesions. By comparison, I-BOP treatment of TPβ -JEG-3 cells enhanced focal adhesion 
size 3 fold compared to TPα and TPΔ 328 expressing cells, although focal adhesion number was maintained overall 
(Fig. 5c). Consistent with the migration data, there was no difference in focal adhesion size and number in TPβ 
cells at baseline indicating the receptor needed to be activated for these effects. The enhanced focal adhesion size 
in TPβ -JEG-3 cells is consistent with the greater adhesion to collagen-based matrices and suggests that enhanced 
adhesion to the matrix is the mechanism by which TPβ activation impedes trophoblast movement.
Focal adhesion kinase (FAK) is centrally involved in the signalling response of integrins, which interact 
directly with the ECM to transmit signals from the extracellular environment38. Consistent with the enhanced 
size of focal adhesions in TPβ -JEG-3 cells, TPβ activation enhanced FAK phosphorylation at Y397 (the FAK auto-
phosphorylation site) up to 1.8 fold (P = 0.014), Y577 by 2 fold (P ≤ 0.011) and Y861 1.5 fold (P ≤ 0.01) compared 
to ∅ - and TPΔ 328-JEG-3 cells (Fig. 5d). Non-significant changes in Y576 and Y925 phosphorylation were also 
observed in I-BOP treated TPβ -JEG-3 cells compared to the other sub-lines. Phosphorylation of Y577 enhances 
FAK activation, which would enhance focal adhesion formation, while phosphorylation of Y861 promotes focal 
adhesion targeting. The enhanced Y577 phosphorylation is indicative of elevated Src activation; however, activa-
tion of Src (denoted by enhanced Y418 and loss of Y529 phosphorylation) only occurred in TPα -JEG-3 cells, not 
TPβ -JEG-3 cells, (Supplementary Fig. S4) indicating the enhanced Y577 phosphorylation is likely the result of 
another Src family member.
Figure 4. TPβ slows and TPα enhances the rate of syncytialisation of trophoblast cells. (a) Transfected 
BeWo cells were incubated for 72 hours with 200 nM I-BOP (vehicle) or 200 nM I-BOP and 100 μ M forskolin 
(forskolin) to induce syncytialisation. Membrane fusion was monitored by staining for E-cadherin (green), 
and cell number demonstrated with DAPI (blue). Cells were imaged at 400x magnification, scale bar: 20 μ m. 
(b) Similarly cultured, transfected BeWo lines were assessed for changes in E-cadherin and syncytin expression 
via immunoblotting. GAPDH was used to control for protein loading and protein bands were quantified using 
densitometry. Data are representative of 3 independent experiments.
www.nature.com/scientificreports/
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Suppression of placental and fetal growth in TPβ-transgenic mice. Our in vitro data suggest 
that TPβ activation inhibits normal trophoblast function; however, whether expression of TPβ is a cause or a 
Figure 5. Migration of trophoblast cells is attenuated by TPβ activation. (a) Motility of transfected JEG-3 cells in 
response to I-BOP (200 nM) was investigated in a chemokinesis assay over 48 hours and compared to vehicle control. 
The distance the cells moved was analysed using TScratch software and expressed as a percentage wound closure, 
n = 6. (b) Adhesion of transfected JEG-3 cells, pre-treated with 200 nM I-BOP for 24 hours, to different extracellular 
matrix proteins (collagen I, □ ; collagen IV, ; fibronectin, ; vitronectin, ■ ) was assessed over a 30 minute period and 
compared to vehicle control. Attachment was quantified using methylene blue staining. (c) Transfected JEG-3 cells, 
treated with vehicle or 200 nM I-BOP, were stained with anti-vinculin antibodies and imaged at 400x magnification via 
fluorescence microscopy to identify focal adhesions. Scale bar: 20 μ m. (d) Changes in FAK activation/phosphorylation 
at specific residues was measured via immunoblotting in transfected JEG-3 cells treated with vehicle or 200nM 
I-BOP. Loading was determined by re-probing the membranes with non-phosphorylated FAK and protein bands 
were quantified using densitometry. The data are represented as mean ± SEM and are representative of 3 independent 
experiments. One-way ANOVA, NS: not significant, * P < 0.05, * * P ≤ 0.01, * * * * P < 0.001.
www.nature.com/scientificreports/
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consequence of the development of IUGR remained unanswered. We characterised the TPβ -transgenic (TPβ -Tg) 
mice to determine a causal role for TPβ in the development of IUGR. The pups born to TPβ -Tg dams were on 
average 26% smaller than pups born to Wt dams (P < 0.001; Fig. 6a,b). In terms of assessed growth potential, 37% 
of all pups born to TPβ -Tg dams fell below the 10th percentile rank consistent with the human classification of 
IUGR. There was a 12% reduction in placental weight for pups born to TPβ -Tg dams compared with the pups 
born to Wt dams (Fig. 6c), although this did not reach significance. Placental diameter was significantly larger 
in growth restricted pups born to TPβ -Tg dams (P = 0.014; Fig. 6d) resulting in the placentae being less dense 
(P = 0.029; Fig. 6e) as well as small. These data indicate that pups born to transgenic mice are growth restricted 
and not just small for gestational age.
The placental pathology of the growth restricted pups born to TPβ -Tg dams was immediately obvious. 
Assessment of the labyrinth in the placentae from TPβ -Tg dams was 10% smaller than its Wt counterparts 
(P = 0.013; Fig. 7a,b). To explain the altered labyrinth size we documented the differentiation/syncytialisation and 
proliferation of trophoblasts in placentae using immunohistochemistry. Consistent with human data, Wt mouse 
placentae were devoid of E-cadherin staining denoting robust fusion in the syncytiotrophoblast layer (Fig. 7c,d). 
The area of E-cadherin expression in the labyrinth of growth restricted pups born to TPβ -Tg dams was 5.3 fold 
higher (Fig. 7c,d) compared to Wt mice. Moreover, the amount of proliferation, as denoted by PCNA staining, 
was 1.8 fold lower in the labyrinth of placentae from pups born to TPβ -Tg dams versus Wt dams (Fig. 7e,f). 
Together these changes in cellular function indicate that placentae of growth restricted litters from TPβ -Tg dams 
have reduced rates of syncytialisation and proliferation. This in vivo data is consistent with the abnormal func-
tion of TPβ overexpressing trophoblasts in vitro and clearly implicates enhanced TPβ -expression on the syncyti-
otrophoblasts of human placentae as causal to the development of IUGR.
Discussion
We report that TP ligands manipulate placentation through direct actions on trophoblasts, in an isoform specific 
fashion. Stimulation of TPα enhanced trophoblast differentiation and proliferation while TPβ activation pre-
vented these activities and inhibited migration. These data have important potential implications for placentation 
as progeny of TPβ -Tg mice displayed fetal growth restriction, accompanied by poor trophoblast proliferation 
and syncytialisation, and reduced placental weight. Most importantly, TPβ expression was enhanced in placental 
Figure 6. TPβ expression in mice produces a robust IUGR phenotype. (a) Representative images of pups 
born to Wt and TPβ -Tg dams at day 18.5 of gestation. All pups were born to n = 14 Wt and n = 7 TPβ -Tg dams. 
(b)Weight of pups born to Wt (□ ) and TPβ -Tg ( ) dams. Pup weight data is representative of pups (n = 89) 
born to Wt dams and pups (n = 48) born to TPβ -Tg dams. Weight (c), diameter (d) and density (e) of the placentae 
from n = 54 pups born to Wt (□ ) and n = 20 pups born to TPβ -Tg ( ) dams. The data are represented as 
mean ± SEM. Independent samples T-test, NS: not significant, * P < 0.05, * * * * P < 0.001.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:28811 | DOI: 10.1038/srep28811
biopsies from growth restricted human pregnancies suggesting isoform switching in the pathogenesis of fetal 
growth restriction. The cause of idiopathic IUGR, especially asymmetrical IUGR, is unknown. The discovery 
of the role of the different TP isoforms in placentation, particularly that dysregulation of TPβ is observed in 
the growth restricted placenta, raises the possibility that this is a significant, yet targetable, pathogenic factor in 
human pregnancy. The acknowledgement of the role of the different TP isoforms in placentation enriches our 
perception of the role for TP activation in pregnancy and expands the repertoire of pathophysiological functions 
ascribed to the receptors.
Our observations add to the dichotomy in the literature over the role of TP isoforms in the regulation of 
health and disease. TPα is known to be pro-angiogenic, whilst TPβ inhibits angiogenic responses39. Despite these 
divergent findings both TP isoforms are pro-tumorigenic in epithelial cells in a tissue/organ specific fashion40,41. 
A previous study documented TP isoform transcripts in primary trophoblasts; however, no studies have doc-
umented TP isoform protein expression. This study showed TPα mRNA was ubiquitous and at high levels in 
primary trophoblasts in vitro but TPβ expression was more variable. However, the outcomes of these pregnancies 
were not known due to the trophoblasts being isolated from first trimester tissue42. Therefore it is possible that 
the trophoblasts with high TPβ expression may have been from placentae with some sort of pathology, such as 
IUGR. Our protein data confirms the robust expression of TPα in trophoblast cells in vitro and in vivo but we do 
not see the same expression of TPβ in placentae from “normal” pregnancies. TPβ expression in placentae from 
pathological pregnancies has not been previously documented and it is unknown how the enhanced TPβ expres-
sion results in IUGR. The control over TP splicing is likely driven by differential promoter utilization43; however, 
the lower expression of TPβ mRNA in IUGR placentae suggests that the mechanism is due to post-transcriptional 
regulation and protein stabilisation. Expression of TPβ , but not TPα , is increased in conditions with elevated free 
radical production44 due to both increased trafficking to the membrane and greater protein stabilization. Such 
changes are well established in the IUGR placenta and may be the reason for TPβ upregulation in disease.
Previous studies on the pathogenic role of TXA2 in IUGR were performed in small animal models25–27 where 
TPβ expression is absent. These data suggest that appropriate activation of TPα may promote healthy placentation 
and angiogenesis; however, overstimulation of TPα may result in ligand-induced receptor desensitization45–47 
essentially creating an environment devoid of TP activation. The bona fide IUGR placenta has been reported 
to produce elevated TXA2 levels22,24 although TXA2 synthase levels have not been documented. Little is known 
about the relative importance of TP isoforms to placentation in humans or the consequences of TP activation on 
trophoblasts. Stimulation of primary human villous cytotrophoblasts (from term placentae) with a TXA2 mimetic 
abrogated differentiation and enhanced apoptosis and p53 expression48. Our data support many of these findings, 
including the failure to differentiate; however, we did not observe any increase in apoptosis. This may reflect dif-
ferences between the low concentrations of TP agonist used here (100 nM or lower), which are more reflective of 
reported (patho)physiological levels49, versus the supra-pathological (10 μ M) doses in the original study48. What 
wasn’t clear from the previous data was the TP isoform responsible for these effects. Our data clearly show that 
TPβ mediates the adverse effects of TXA2 on placentation, with neither TP∆ 328 nor TPα producing the same 
responses. These data further accentuate the divergent roles for TPα and TPβ as human-specific disease modifiers 
and emphasize the need for greater understanding of the biology of the individual isoforms. The signalling that 
perturbs trophoblast function and placentation resides in the divergent C-terminal residues of TPβ . Indeed, we 
have previously shown that the C-terminus of TPβ is all that is required for the inhibition of angiogenesis39. The 
79 residue cytoplasmic tail of TPβ is a poor discriminator of G-protein coupling (TPα and TPβ share > 70% of Gα 
units as second messengers) but has significantly different protein-protein interactions than that of TPα . Recently, 
protein-protein interactions of the tail of TPβ have been shown to manipulate the behavior of smooth muscle and 
cancer cells50,51 independent of G-protein coupling. However, both interactions enhance proliferation and migra-
tion in the respective cell types and interactions are yet to be identified that inhibit cellular function as described 
here. We believe that pathways unrelated to G-protein activation, mediated through direct interaction of proteins 
with the cytoplasmic tail of TPβ , regulate the negative effects of TPβ on placentation and trophoblast migration.
The primary deficit in the original report of the TPβ -Tg mice was a decrease in placental and pup size52; 
however, reductions in pup and placental weights were not quantified nor was any basis for the growth restric-
tion explored. In the previous study only homozygous transgenic mice showed the IUGR phenotype, which 
could have resulted from the mixed genetic background (SV129xC57Bl/6). Our cohort have been backcrossed 
to C57Bl/6 for a total of 16 generations and still maintain the growth restricted phenotype suggesting that TPβ 
expression is the cause of the growth restriction. The trophoblast layer of these placentae was poorly formed with 
smaller labyrinthine zones, most likely a result of the diminished trophoblast proliferation caused by TPβ activa-
tion. This is likely to have been compounded by the anti-angiogenic effects of TPβ 39, which would have further 
limited placental growth. The failure to syncytialise would have compromised fetal growth, not only by reducing 
the transport of nutrients and waste products of metabolism, but because the integration of fetomaternal signal-
ling would be compromised in these placentae53. Again, the anti-angiogenic effects of TPβ may also play a role in 
fetal growth with vascular bed development possibly retarded in the TPβ -Tg pups. Thus, this model represents a 
unified theory for the origins of idiopathic IUGR in humans and a new target for therapeutic development.
The identification that TXA2 levels are elevated in IUGR, compared to “normal” pregnancies, has resulted 
in targeting TXA2 generation to provide therapeutic benefit. As in cardiovascular disease, these attempts have 
primarily focussed on low-dose aspirin (60–150 mg/day) to prevent TXA2 synthesis by platelets. Aspirin crosses 
the placenta and has a favourable safety profile in pregnancy48,54. Despite this, the outcomes of large scale clinical 
trials for the use of aspirin to prevent IUGR have been largely negative. Historically, initiation of aspirin therapy 
after 16 weeks gestation53–55 has been shown to be less beneficial than early in pregnancy23,54,55. However, whether 
IUGR is associated with a normotensive or hypertensive pregnancy also changes whether fetal, or maternal and 
fetal circulations are involved, which changes the response to aspirin therapy41. Moreover, aspirin appears to pref-
erentially inhibit TXA2 production in villous cell types other than the trophoblast45. Our data would suggest that 
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Figure 7. TPβ expression in mice reduces labyrinthine formation and prevents trophoblast proliferation and 
differentiation as part of the IUGR phenotype. (a) Representative images of H&E stained sections of placentae from 
pups born to Wt (n = 89) and TPβ -Tg (n = 48) dams at day 18.5 of gestation. (b) From the H&E stained sections, 
the size of the labyrinthine zone of placentae from pups (n = 9) born to Wt (□ ) dams and pups (n = 31) born to TPβ 
-Tg ( ) dams was elucidated using ImageJ software. Representative images (c) and quantification (d) of E-cadherin 
expression in the labyrinthine zone in placentae from pups (n = 47) born to Wt (□ ) dams and pups (n = 59) born 
to TPβ -Tg ( ) dams. Representative images (e) and quantification (f) of proliferation (PCNA staining) in the 
labyrinthine zone in placentae from pups (n = 53) born to Wt (□ ) dams and pups (n = 59) born to TPβ -Tg ( ) dams. 
All sections stained for E-cadherin and PCNA were imaged at 200x magnification, scale bar: 100 μ m. The data are 
represented as mean ± SEM. Independent samples T-test, * P < 0.05, * * * * P < 0.001.
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all these factors are issues in the effectiveness of aspirin therapy as TPβ is activated not just in response to TXA2 
but also isoprostanes18. Administration of aspirin to promote appropriate placentation, and negate the effects of 
TPβ , would only be effective early in pregnancy and may need to target both maternal and fetal circulations, as 
TPβ is expressed on both fetal and maternal endothelial cells and syncytiotrophoblasts. As such, current thera-
pies for IUGR are insufficient as they do not appropriately target TPβ activation, resulting in persistent disease. 
Conversely, the use of dual action TP/TXA2 synthase antagonists has not been trialled in IUGR, although these 
drugs are effective in animal models of IUGR31, and may represent a better therapeutic option than aspirin.
Collectively our data suggest that the upregulation of TPβ in placentae of IUGR pregnancies initiates a cas-
cade which compromises trophoblast proliferation, invasive potential and differentiation, to produce an environ-
ment unable to support placental growth and fetal development. Our data are the first to elucidate the role of the 
human-specific isoform of TP, TPβ , as a pathogenic component in the development of IUGR and suggests that target-
ing TPβ activation, or TP splicing, offers a therapeutic avenue for IUGR, which currently has no effective therapies.
Materials and Methods
Materials. The TXA2 mimetic I-BOP ([1S-[1α ,2α (Z),3β (1E,3S* ),4α ]]-7-[3-[3-hydroxy-4-(4-iodophe-
noxy)-1-butenyl]-7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid) was from Cayman Chemical. Forskolin and 
L-Mimosine were from Sigma Aldrich. All cell culture reagents were from Life Technologies, immunohistochem-
ical regents from DAKO and general chemicals from Sigma-Aldrich unless otherwise stated.
Tissue collection. This study was performed in accordance with the guidelines approved by the Northern 
Sydney Local Health District Human Research Ethics Committee, St Leonards, NSW, Australia and was assigned 
the site specific assessment number 0912–348M and the Australian national ethics application form number 
HREC/09/HARBR/165. Collection of human placental tissue was performed with written informed consent 
obtained prior to delivery. Placentae were collected from non-labouring or minimally labouring women at 
delivery by lower caesarean section from pregnancies complicated by IUGR or gestationally matched control 
pregnancies. Patient populations were matched for body mass index (BMI) and smoking, gestational diabetes, 
pre-existing hypertension and pre-eclampsia were exclusion criteria (Table 1). IUGR was diagnosed prior to 
delivery by ultrasound, where estimated fetal weight of less than the 10th percentile for gestational age was associ-
ated with elevated fetoplacental vascular resistance defined as the Systolic/Diastolic ratio over the 95th percentile 
or absent or reversed flow in diastole in the umbilical artery, and confirmed by weight at birth. Placental tissue 
was washed in sterile saline and either snap frozen in liquid nitrogen or fixed in 10% (v/v) neutral buffered forma-
lin prior to paraffin embedding or extraction of protein/RNA.
Cell culture and transfection with vectors encoding TP isoforms. Choriocarcinoma cell lines (BeWo 
and JEG-3) were maintained in RPMI culture medium supplemented with 10% (v/v) fetal calf serum, 2 mM 
L-glutamine, 10 μ g/mL penicillin and 10 U/mL streptomycin. Sub-confluent monolayers were passaged weekly 
using TrypLE Express. To ensure maximal TP activation, BeWo and JEG-3 cells were treated with 200 nM I-BOP. 
Syncytialisation of BeWo cells was induced by treating with 100 μ M forskolin56.
The coding sequence for TPα , TPβ , and the deletion mutant (TPΔ 328) were cloned into pcDNA3.1. TP recep-
tor constructs were introduced into BeWo and JEG-3 cells using Effectene (Qiagen Pty Ltd.) or Lipofectamine 
2000 (Life Technologies) transfection reagents, respectively, following the manufacturers’ instructions. Empty 
vector (∅ ) was used as a control. Stable expression was achieved in BeWo and JEG-3 cells after antibiotic selection 
using 200 μ g/mL and 400 μ g/mL Geneticin (G418 sulfate), respectively. Receptor expression was confirmed using 
semi-quantitative RT-PCR on RNA from stably expressing cells.
Quantitative gene expression using Droplet Digital PCR. RNA isolation was performed using TRIzol 
Reagent according to the manufacturer’s recommendations. Tissue samples were weighed, placed into an M-tube 
with the appropriate amount of TRIzol Reagent and disaggregated using a gentleMACS Dissociator (Miltenyi 
Biotec). Cell lines were scraped directly into TRIzol Reagent. RNA quality and concentration were assessed 
using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific) and subsequently 1 μ g RNA was reverse 
transcribed to cDNA using BioScript Reverse Transcriptase (Bioline). Gene expression was quantitated using 
the QX200 Droplet Digital PCR (ddPCR) System (Bio-Rad). Reactions were prepared using the QX200 ddPCR 
EvaGreen Supermix, 50 ng cDNA and the following primers which span the intron-exon boundary responsible 
for alternative splicing of TP or an internal control gene (HPRT1):
TP (Total) Forward 5′ -CGGGTTCAAGCGATTCTCG-3′ 
TP (Total) Reverse 5′ -CCTGTTGGAGGTTCAAAAGGAAG-3′ 
TPα Forward 5′ -CGCACCACGGAGAAGGAG-3′ 
TPα Reverse 5′ -CTGGGGCTGGAGGGACAG-3′ 
TPβ Forward 5′ -CTTCTGGTCTTCATCGCC-3′ 
TPβ Reverse 5′ -AAAGGAAGCAACTGTACCCC-3′ 
HPRT1 Forward (internal control) 5′ -GTTTGTTGTAGGATATGCCCTTGAC-3′ 
HPRT1 Reverse 5′ -GACTCCAGATGTTTCCAAACTCAAC-3′ 
Droplets were generated from the reactions using QX200 Droplet Generation Oil for EvaGreen on the QX200 
Droplet Generator (Bio-Rad) according to the manufacturer’s instructions. The droplets were cycled on a T100 
Gradient Thermal Cycler (Bio-Rad) according to the manufacturer’s protocol using an annealing temperature of 60 °C. 
The droplets were analysed using the QX200 Droplet Reader and analysed using QuantaSoft Software (Bio-Rad). 
Detection of < 15,000 droplets in a sample indicated poor quality and was therefore excluded from the analysis.
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Chemokinesis assay. JEG-3 cells were chosen as BeWo cells did not migrate well in these assays. Transfected 
JEG-3 cells were grown to confluence and motility assessed as previously described39 in the presence of I-BOP 
(200 nM) or vehicle control (equivalent volume of ethanol). Media was supplemented with L-Mimosine (400 μ M) 
to negate the effects of proliferation on the outcome of the assay. Photographs were taken at the time of injury 
(0 hours) and after 24 and 48 hours. T-Scratch software was used to quantify the distance migrated and the migra-
tion of I-BOP treated cells was then normalised relative to vehicle control treated cells.
Adhesion assay. Adhesion of JEG-3 cells to matrix proteins, including collagen I (Life Technologies), col-
lagen IV (Sigma-Aldrich), fibronectin (Life Technologies) and vitronectin (Promega) was assessed as previously 
described39. JEG-3 cells were cultured in the presence of 200 nM I-BOP, or vehicle control, for 24 hours prior to 
the assay. Cells were detached using TrypLE Express, plated into pre-coated 24 well plates at 1 × 105 cells/well and 
incubated for 37 °C for 30 minutes. After washing to remove unattached cells, wells were fixed with 10% (v/v) neu-
tral buffered formalin and adhesion detected by staining with 1% (w/v) methylene blue as previously described57.
Cell proliferation, apoptosis and cell cycle analysis by flow cytometry. JEG-3 and BeWo cell prolif-
eration was assessed by seeding 2 × 104 cells/well into 24 well plates. Cells were cultured in the presence of 200 nM 
I-BOP, or vehicle control, for up to 7 days. Cells were enumerated by cell counting or staining with 1% (w/v) 
methylene blue. Cell cycle and apoptosis analyses were performed on randomly cycling, and growth arrested, 
BeWo cells as previously described58. DNA content was analysed using a BD FACSCalibur Flow Cytometer and 
ModFit software. Apoptosis was quantified as the hypodiploid peak in these samples.
SDS PAGE, slot blots and immunoblotting. Protein lysates from transfected BeWo and JEG-3 
cell lines were obtained as described59. For placental tissue, biopsies were weighed, placed into an M-tube 
with the appropriate amount of lysis buffer containing 1% (v/v) Y30 and disaggregated using a gentleMACS 
Dissociator (Miltenyi Biotec). For phospho-proteins, lysates were prepared using hot SDS-PAGE buffer as pre-
vious described58. Concentration of protein lysates was estimated using the Pierce BCA Protein Assay Kit (Life 
Technologies) and 30 μ g separated by SDS-PAGE under reducing conditions on 8%-10% (w/v) polyacrylamide 
gels. After transfer to PVDF membranes, immunoblotting was performed as previously described39 for: Cyclin 
A, B1, D1, E, p16, p21, p27, p53 (1:1000, Santa Cruz Biotechnology) and Retinoblastoma Protein (Rb) (pSer780, 
pSer795 and pSer807/811; 1:1000, Cell Signaling Technology), E-cadherin and syncytin (Santa Cruz Biotechnology), 
FAK (pY397, pY576/577, pY925; 1:2000, Life Technologies) and Src (pY418, pY529; 1:2000, Life Technologies). Total pro-
tein content was assessed by immunoblotting for GAPDH (Santa Cruz Biotechnology) or unphosphorylated ver-
sions of the proteins of interest (FAK/Src/Rb; 1:2000, Santa Cruz Biotechnology and Cell Signaling Technology).
For slot blotting, 100 μ g of protein lysate from placental samples was loaded into a manifold (Bio-Rad) and 
adsorbed onto nitrocellulose membranes under vacuum. Membranes were probed for total TP content (Santa 
Cruz Biotechnology), TPα , TPβ (using our in-house antibodies)40 and loading for cellular content was assessed 
using a Histone H1 antibody (1:1000, Santa Cruz Biotechnology). Protein expression by immunoblotting was 
detected using the appropriate HRP-conjugated secondary antibodies (1:3000, Dako) in combination with an 
enhanced chemiluminescence detection system (PerkinElmer) and ImageQuant LAS 4000 (GE Healthcare). 
Densitometry of protein bands were quantitated using ImageJ software.
Immunofluorescent imaging for cell membrane structure and focal adhesion complexes. Cells 
were plated onto glass coverslips pre-coated with 0.2% (w/v) gelatine and 0.2 μ g/mL fibronectin. For syncytialisa-
tion assays BeWo cell culture medium was supplemented with 200 nM I-BOP, with or without 100 μ M forskolin, 
and replenished every 24 hours over 3 days. For detection of focal adhesions, JEG-3 cells were exposed to 200 nM 
I-BOP, or vehicle control, for 24 hours. Immunostaining after fixation in 4% (w/v) paraformaldehyde was per-
formed as previously described39, which involved incubation with antibodies against E-cadherin (1:500, Santa 
Cruz Biotechnology) or vinculin (Sigma Aldrich) and detected using an Alexa Fluor 488 conjugated second anti-
body (1:800; Molecular Probes). Coverslips were mounted onto glass slides and counterstained with DAPI. Slides 
were imaged using an Olympus DP71 fluorescent microscope at 400x magnification using Olympus DP controller 
software and then images were overlayed using ImageJ software.
Estimates of placental structure in TPβ-Tg and wild-type mice. The animal component of this 
study was performed in accordance with the guidelines approved by the Kolling Institute of Medical Research’s 
Animal Ethics Committee, St Leonards, NSW, Australia and was assigned the protocol number 1311–015A. 
TPβ -transgenic (TPβ -Tg) mice52 were bred from their original mixed C57Bl6/SV129 background to be con-
genic on the C57Bl/6J background (> 15 generations). Mice were bred as hemizygote crosses with wild-type (Wt) 
C57Bl/6J mice. Mice were housed within the Kearns facility at the Kolling Institute within individually vented 
cages under PC2 conditions and had food and water ad libitum. Timed intra-strain mating of Wt and TPβ -Tg 
mice (10–12 weeks old) were performed using nulliporous female mice. Females with copulation plugs were 
separated at E0.5 and pregnancies carried until E18.5 when mice were euthanized using inhalation anaesthetic, 
tissues collected and biometrics on the pups assessed. The cohort of mice included 89 pups born to 14 Wt dams 
and 48 pups born to 7 TPβ -Tg dams. Quantification of labyrinthine area was performed using ImageJ software.
Immunohistochemistry. Formalin fixed, paraffin embedded human and mouse placental tissues were sec-
tioned (4 μ m), dewaxed and rehydrated through graded alcohols. Haematoxylin and eosin (H&E) staining was 
performed to identify placental structure. Immunohistochemistry (IHC) was performed as previously described60 
with antigen retrieval performed at 99 °C for 20 minutes in EnVision FLEX retrieval solution (high pH, Dako). 
Slides were incubated in sequenza racks (Thermo Fisher Scientific) overnight at 4 °C with our primary antibodies 
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against TPα and TPβ (1:400; raised in-house)40, E-cadherin (2 μ g/mL; Cell Signaling Technology) and PCNA 
(1 μ g/mL; Santa Cruz Biotechnology) or anti-rabbit IgG isotype control at equivalent concentrations. NovaRed 
peroxidase HRP substrate kit (Vector Laboratories) was used to visualise the staining following the manufac-
turer’s instructions. Sections were counterstained using Mayer’s haematoxylin (Merck Millipore) and mounted 
with Eukitt mounting medium (Grale HDS). All placental sections were imaged using a Nikon ECLIPSE 80i light 
microscope with a Nikon Digital Sight Control Unit and Nikon Digital Sight DS-5M camera at 200x magnifica-
tion using NIS-Elements software version 3.
Statistical analyses. Statistical analyses based on One-way analysis of variance (ANOVA) were performed 
using SPSS (version 20). LSD or Games-Howell post-hoc tests were used to analyse densitometry readings from 
western blot analyses and percentage wound closure in scratch assays. Cell proliferation data were assessed using 
a general linear model analysis as well as linear contrasts within the program R. All other data was analysed using 
Independent samples T-tests or Mann-Whitney U non-parametric tests using SPSS. All data are displayed as 
mean ± standard error of the mean (SEM).
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